Paul Bunn, MD, University of Colorado Cancer Center

Articles by Paul Bunn, MD, University of Colorado Cancer Center

Reducing the Impact of Chemotherapy-Induced Myelosuppression

ByPaul Bunn, MD, University of Colorado Cancer Center,Gary H. Lyman, MD, MPH, FASCO, FRCP, University of Washington School of Medicine

September 16th 2020

CDK4/6 Inhibitors & Myelopreservation in Other Cancers

ByPaul Bunn, MD, University of Colorado Cancer Center,Gary H. Lyman, MD, MPH, FASCO, FRCP, University of Washington School of Medicine

September 16th 2020

CDK4/6 Inhibitors for SCLC: Trials of Interest

ByPaul Bunn, MD, University of Colorado Cancer Center,Gary H. Lyman, MD, MPH, FASCO, FRCP, University of Washington School of Medicine

September 16th 2020

Chemotherapy-Induced Myelosuppression in SCLC: CDK4/6 Inhibition

ByPaul Bunn, MD, University of Colorado Cancer Center,Gary H. Lyman, MD, MPH, FASCO, FRCP, University of Washington School of Medicine

September 16th 2020

Analyses of CDK4/6 Inhibitors for Myelopreservation

ByPaul Bunn, MD, University of Colorado Cancer Center,Gary H. Lyman, MD, MPH, FASCO, FRCP, University of Washington School of Medicine

September 16th 2020

CDK4/6 Inhibitors and Myelopreservation

ByPaul Bunn, MD, University of Colorado Cancer Center,Gary H. Lyman, MD, MPH, FASCO, FRCP, University of Washington School of Medicine

September 16th 2020

Chemotherapy-Induced Myelosuppression & COVID-19

ByPaul Bunn, MD, University of Colorado Cancer Center,Gary H. Lyman, MD, MPH, FASCO, FRCP, University of Washington School of Medicine

September 16th 2020

Management of Chemo-Induced Myelosuppression

ByPaul Bunn, MD, University of Colorado Cancer Center,Gary H. Lyman, MD, MPH, FASCO, FRCP, University of Washington School of Medicine

September 16th 2020

Chemotherapy Use & Chemotherapy-Induced Myelosuppression

ByPaul Bunn, MD, University of Colorado Cancer Center,Gary H. Lyman, MD, MPH, FASCO, FRCP, University of Washington School of Medicine

September 16th 2020

KRAS G12C Inhibition in Advanced NSCLC: MRTX849

ByPaul Bunn, MD, University of Colorado Cancer Center,Alexander Drilon, MD, Memorial Sloan Kettering Cancer Center,Jonathan Riess, MD, MS, UC Davis Comprehensive Cancer Center

August 3rd 2020

KRAS G12C Inhibition in Advanced NSCLC: AMG 510

ByPaul Bunn, MD, University of Colorado Cancer Center,Alexander Drilon, MD, Memorial Sloan Kettering Cancer Center,Jonathan Riess, MD, MS, UC Davis Comprehensive Cancer Center

August 3rd 2020

Development of KRAS G12C-Targeted Therapy in NSCLC

ByPaul Bunn, MD, University of Colorado Cancer Center,Alexander Drilon, MD, Memorial Sloan Kettering Cancer Center,Jonathan Riess, MD, MS, UC Davis Comprehensive Cancer Center

August 3rd 2020

Systemic Therapy for KRAS+ Advanced NSCLC

ByPaul Bunn, MD, University of Colorado Cancer Center,Alexander Drilon, MD, Memorial Sloan Kettering Cancer Center,Jonathan Riess, MD, MS, UC Davis Comprehensive Cancer Center

August 3rd 2020

Counseling Patients With NSCLC When KRAS is Detected

ByPaul Bunn, MD, University of Colorado Cancer Center,Alexander Drilon, MD, Memorial Sloan Kettering Cancer Center,Jonathan Riess, MD, MS, UC Davis Comprehensive Cancer Center

August 3rd 2020

Testing for KRAS Mutations in NSCLC

ByPaul Bunn, MD, University of Colorado Cancer Center,Alexander Drilon, MD, Memorial Sloan Kettering Cancer Center,Jonathan Riess, MD, MS, UC Davis Comprehensive Cancer Center

August 3rd 2020

KRAS Mutations in Solid Tumors

ByPaul Bunn, MD, University of Colorado Cancer Center,Alexander Drilon, MD, Memorial Sloan Kettering Cancer Center,Jonathan Riess, MD, MS, UC Davis Comprehensive Cancer Center

August 3rd 2020

Current Management of Oncogene-Driven NSCLC

ByPaul Bunn, MD, University of Colorado Cancer Center,Alexander Drilon, MD, Memorial Sloan Kettering Cancer Center,Jonathan Riess, MD, MS, UC Davis Comprehensive Cancer Center

August 3rd 2020

Latest Updated Articles

Analyses of CDK4/6 Inhibitors for Myelopreservation
September 16th 2020
Counseling Patients With NSCLC When KRAS is Detected
August 3rd 2020
Testing for KRAS Mutations in NSCLC
August 3rd 2020
CDK4/6 Inhibitors & Myelopreservation in Other Cancers
September 16th 2020
Reducing the Impact of Chemotherapy-Induced Myelosuppression
September 16th 2020
Current Management of Oncogene-Driven NSCLC
August 3rd 2020

Paul Bunn, MD, University of Colorado Cancer Center

Articles by Paul Bunn, MD, University of Colorado Cancer Center

Reducing the Impact of Chemotherapy-Induced Myelosuppression

CDK4/6 Inhibitors & Myelopreservation in Other Cancers

CDK4/6 Inhibitors for SCLC: Trials of Interest

Chemotherapy-Induced Myelosuppression in SCLC: CDK4/6 Inhibition

Analyses of CDK4/6 Inhibitors for Myelopreservation

CDK4/6 Inhibitors and Myelopreservation

Chemotherapy-Induced Myelosuppression & COVID-19

Management of Chemo-Induced Myelosuppression

Chemotherapy Use & Chemotherapy-Induced Myelosuppression

KRAS G12C Inhibition in Advanced NSCLC: MRTX849

KRAS G12C Inhibition in Advanced NSCLC: AMG 510

Development of KRAS G12C-Targeted Therapy in NSCLC

Systemic Therapy for KRAS+ Advanced NSCLC

Counseling Patients With NSCLC When KRAS is Detected

Testing for KRAS Mutations in NSCLC

KRAS Mutations in Solid Tumors

Current Management of Oncogene-Driven NSCLC

Latest Updated Articles

Trending on OncLive

Frontline Sac-TMT Plus Pembrolizumab Meets PFS End Point in PD-L1–Negative, Nonsquamous NSCLC

The OncFive: Top Oncology Articles for the Week of 7/12

Five Under 5: Top Oncology Videos for the Week of 7/12

CD33-Directed CAR T-Cell Therapies Elicit Complete Remissions in Relapsed/Refractory AML

Imaging Cadence, Radiation Timing, and Osimertinib Dosing Frame CNS Management Decisions in EGFR-Mutated NSCLC